REFERENCES
2. Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathol. 2020;140:417-47.
3. Zhang Y, Wang Y, Shi C, Shen M, Lu F. Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease. Transl Neurodegener. 2021;10:6.
4. Ge YJ, Xu W, Ou YN, et al. Retinal biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev. 2021;69:101361.
5. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44-53.
6. Currant H, Hysi P, Fitzgerald TW, et al; UK Biobank Eye and Vision Consortium. Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. PLoS Genet. 2021;17:e1009497.
7. Cheung CY, Ikram MK, Chen C, Wong TY. Imaging retina to study dementia and stroke. Prog Retin Eye Res. 2017;57:89-107.
8. Kashani AH, Asanad S, Chan JW, et al. Past, present and future role of retinal imaging in neurodegenerative disease. Prog Retin Eye Res. 2021;83:100938.
9. der Heide FCT, Khawaja A, Berendschot TTJM, et al; Maastricht Study Consortium, UK Biobank Eye & Vision Consortium, E3 consortium. Associations of inner retinal layers with risk of incident dementia: an individual participant data analysis of four prospective cohort studies. Alzheimers Dement. 2024;20:211-20.
10. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
11. Smith G, Holmes MV, Davies NM, Ebrahim S. Mendel’s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues. Eur J Epidemiol. 2020;35:99-111.
12. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. Nat Rev Methods Primers. 2022;2:6.
13. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement. JAMA. 2021;326:1614-21.
15. Bellenguez C, Küçükali F, Jansen IE, et al; EADB. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54:412-36.
16. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414-30.
17. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35:4851-3.
18. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005-12.
19. Burgess, S. & Thompson, S. G. Mendelian randomization: methods for causal inference using genetic variants. CRC Press; 2021.
20. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755-64.
21. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2019;4:186.
22. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377-89.
23. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28:30-42.
24. Milne RL, Kuchenbaecker KB, Michailidou K, et al; ABCTB Investigators. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49:1767-78.
25. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46:1985-98.
26. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:693-8.
27. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13:e1007081.
28. Man S, Chen B, Zhang Y, et al. The Associations between cataracts and Alzheimer’s disease: a bidirectional two-sample mendelian randomization study. J Alzheimers Dis. 2023;92:1451-8.
29. Chen F, Wen W, Long J, et al. Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes. Int J Cancer. 2022;151:372-80.
30. Locke AE, Kahali B, Berndt SI, et al; LifeLines Cohort Study. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518:197-206.
31. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50:1219-24.
32. López-de-Eguileta A, Lage C, López-García S, et al. Ganglion cell layer thinning in prodromal Alzheimer’s disease defined by amyloid PET. Alzheimers Dement (N Y). 2019;5:570-8.
33. La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79:90-109.
34. Wang M, Zhu Y, Shi Z, Li C, Shen Y. Meta-analysis of the relationship of peripheral retinal nerve fiber layer thickness to Alzheimer’s disease and mild cognitive impairment. Shanghai Arch Psychiatry. 2015;27:263-79.
35. Lian TH, Jin Z, Qu YZ, et al. The Relationship between retinal nerve fiber layer thickness and clinical symptoms of Alzheimer’s disease. Front Aging Neurosci. 2020;12:584244.
36. Ascaso FJ, Cruz N, Modrego PJ, et al. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neurol. 2014;261:1522-30.
37. Javaid FZ, Brenton J, Guo L, Cordeiro MF. Visual and ocular manifestations of Alzheimer’s disease and their use as biomarkers for diagnosis and progression. Front Neurol. 2016;7:55.
38. Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst). 2015;1:136-43.
39. Almeida ALM, Pires LA, Figueiredo EA, et al. Correlation between cognitive impairment and retinal neural loss assessed by swept-source optical coherence tomography in patients with mild cognitive impairment. Alzheimers Dement (Amst). 2019;11:659-69.
40. Eraslan M, Çerman E, Çekiç O, et al. Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease. Turk J Med Sci. 2015;45:1106-14.
41. Ito Y, Sasaki M, Takahashi H, et al. Quantitative assessment of the retina using OCT and associations with cognitive function. Ophthalmology. 2020;127:107-18.
42. Chan VTT, Sun Z, Tang S, et al. Spectral-Domain OCT measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology. 2019;126:497-510.
43. den Haan J, van de Kreeke JA, Konijnenberg E, et al. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer’s disease. Alzheimers Dement (Amst). 2019;11:463-71.
44. Sánchez D, Castilla-Marti M, Marquié M, et al. Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer’s disease in a memory clinic. Sci Rep. 2020;10:1580.
45. Santos CY, Johnson LN, Sinoff SE, Festa EK, Heindel WC, Snyder PJ. Change in retinal structural anatomy during the preclinical stage of Alzheimer’s disease. Alzheimers Dement (Amst). 2018;10:196-209.
46. van de Kreeke JA, Nguyen HT, Konijnenberg E, et al. Longitudinal retinal layer changes in preclinical Alzheimer’s disease. Acta Ophthalmol. 2021;99:538-44.
47. Shin JY, Choi EY, Kim M, Lee HK, Byeon SH. Changes in retinal microvasculature and retinal layer thickness in association with apolipoprotein E genotype in Alzheimer’s disease. Sci Rep. 2021;11:1847.
48. Yeh TC, Kuo CT, Chou YB. Retinal microvascular changes in mild cognitive impairment and Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression. Front Aging Neurosci. 2022;14:860759.
49. Haan J, Janssen SF, van de Kreeke JA, Scheltens P, Verbraak FD, Bouwman FH. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimers Dement (Amst). 2018;10:49-55.
